Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
December 20, 2021updated 07 Jan 2022 7:17am

Covid-19 pivotal trials slightly decrease for 2021

There have been 12 fewer trials for Covid-19 categorised as pivotal or registration studies this year compared with last year.

By GlobalData Healthcare

Since December 2019, the emergence of the Covid-19 pandemic has caused both industry and non-industry sponsors to hunt for suitable therapeutics and vaccines for the disease. A global effort in tackling this disease has meant both sponsors and regulatory agencies have had to shift priority from standard practice to focusing on delivering effective vaccines and drugs. Sponsors have used pivotal trials for Covid-19 to gain marketing approval from regulatory authorities such as the US Food and Drug Administration (FDA) or European Medicines Agency (EMA).

A pivotal or registration clinical trial is a trial seeking to prove the efficacy of new therapeutics and vaccines. According to GlobalData’s Clinical Trials Database, there were 53 trials for Covid-19 categorised as pivotal or registration studies last year, whereas this year, this decreased to 41 trials. The value for the coming year is still ongoing. These values may seem small; this is due to sponsors focusing on expedited approval programmes, especially for Covid-19. Under accelerated approval and fast-track programmes by regulatory agencies, therapeutics and vaccines that prove to be effective for serious or life-threatening diseases can receive conditional approval. With the emergence of the new Omicron variant, the focus has been placed on the efficacy of booster vaccinations.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU